These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28467918)

  • 1. Higher antitumor activity of trabectedin in germline BRCA2 carriers with advanced breast cancer as compared to BRCA1 carriers: A subset analysis of a dedicated phase II trial.
    Ghouadni A; Delaloge S; Lardelli P; Kahatt C; Byrski T; Blum JL; Gonçalves A; Campone M; Nieto A; Alfaro V; Cullell-Young M; Lubinski J
    Breast; 2017 Aug; 34():18-23. PubMed ID: 28467918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.
    Delaloge S; Wolp-Diniz R; Byrski T; Blum JL; Gonçalves A; Campone M; Lardelli P; Kahatt C; Nieto A; Cullell-Young M; Lubinski J
    Ann Oncol; 2014 Jun; 25(6):1152-8. PubMed ID: 24692579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
    Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
    Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer.
    Blum JL; Gonçalves A; Efrat N; Debled M; Conte P; Richards PD; Richards D; Lardelli P; Nieto A; Cullell-Young M; Delaloge S
    Breast Cancer Res Treat; 2016 Jan; 155(2):295-302. PubMed ID: 26749361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
    Lorusso D; Scambia G; Pignata S; Sorio R; Amadio G; Lepori S; Mosconi A; Pisano C; Mangili G; Maltese G; Sabbatini R; Artioli G; Gamucci T; Di Napoli M; Capoluongo E; Ludovini V; Raspagliesi F; Ferrandina G
    Ann Oncol; 2016 Mar; 27(3):487-93. PubMed ID: 26681678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.
    Awada A; Cortés J; Martín M; Aftimos P; Oliveira M; López-Tarruella S; Espie M; Lardelli P; Extremera S; Fernández-García EM; Delaloge S
    Clin Breast Cancer; 2016 Oct; 16(5):364-371. PubMed ID: 27266804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
    Cruz C; Llop-Guevara A; Garber JE; Arun BK; Pérez Fidalgo JA; Lluch A; Telli ML; Fernández C; Kahatt C; Galmarini CM; Soto-Matos A; Alfaro V; Pérez de la Haza A; Domchek SM; Antolin S; Vahdat L; Tung NM; Lopez R; Arribas J; Vivancos A; Baselga J; Serra V; Balmaña J; Isakoff SJ
    J Clin Oncol; 2018 Nov; 36(31):3134-3143. PubMed ID: 30240327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study.
    Boni V; Pistilli B; Braña I; Shapiro GI; Trigo J; Moreno V; Castellano D; Fernández C; Kahatt C; Alfaro V; Siguero M; Zeaiter A; Longo F; Zaman K; Antón A; Paredes A; Huidobro G; Subbiah V
    ESMO Open; 2022 Oct; 7(5):100571. PubMed ID: 36037567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin as a chemotherapy option for patients with BRCA deficiency.
    Monk BJ; Lorusso D; Italiano A; Kaye SB; Aracil M; Tanović A; D'Incalci M
    Cancer Treat Rev; 2016 Nov; 50():175-182. PubMed ID: 27710871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
    McMeekin DS; Lisyanskaya A; Crispens M; Oza AM; Braly P; Doering D; Bayever E; Michiels B; Markman M
    Gynecol Oncol; 2009 Aug; 114(2):288-92. PubMed ID: 19476988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
    García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
    Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.
    Ferrandina G; Salutari V; Vincenzi B; Marinaccio M; Naglieri E; Loizzi V; Carpano S; Amadio G; Tonini G; Scambia G; Lorusso D
    Gynecol Oncol; 2013 Sep; 130(3):505-10. PubMed ID: 23774301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trabectedin mechanism of action and platinum resistance: molecular rationale.
    Ray-Coquard I
    Future Oncol; 2017 Oct; 13(23s):17-21. PubMed ID: 29020822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
    Adam JP; Boumedien F; Letarte N; Provencher D
    Gynecol Oncol; 2017 Oct; 147(1):47-53. PubMed ID: 28751117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.
    Hensley ML; Patel SR; von Mehren M; Ganjoo K; Jones RL; Staddon A; Rushing D; Milhem M; Monk B; Wang G; McCarthy S; Knoblauch RE; Parekh TV; Maki RG; Demetri GD
    Gynecol Oncol; 2017 Sep; 146(3):531-537. PubMed ID: 28651804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
    Le Cesne A; Cresta S; Maki RG; Blay JY; Verweij J; Poveda A; Casali PG; Balaña C; Schöffski P; Grosso F; Lardelli P; Nieto A; Alfaro V; Demetri GD
    Eur J Cancer; 2012 Nov; 48(16):3036-44. PubMed ID: 22749255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.